Second Sight Medical Pro... Stock Price - EYES

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Second Sight Medical Products Inc EYES NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.0097 -1.1% 0.8753 0.91 0.851181 0.91 0.885 15:42:20
Bid Price Ask Price Spread Spread % News
0.8701 0.8803 0.0102 1.16% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
366 98,525 $ 0.8831509 $ 87,012 168,203 0.6351 - 1.56
Last Trade Time Type Quantity Stock Price Currency
15:42:20 30 $ 0.8701 USD

Second Sight Medical Pro... Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 107.73M 124.59M $ -35.09M -0.53 - 123.73M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Second Sight Medical Pro... News

Loading Messages....

Latest EYES Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EYES Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.740.950.710.8214191251,3440.135318.28%
1 Month0.80290.950.70620.8157143177,8950.07249.02%
3 Months0.811.120.660.8490847188,3260.06538.06%
6 Months0.951.120.640.8174645197,505-0.0747-7.86%
1 Year1.531.560.63510.8969001320,466-0.6547-42.79%
3 Years2.002.830.63511.46415,393-1.12-56.24%
5 Years17.0024.020.63515.84495,539-16.12-94.85%

Second Sight Medical Pro... Description

Second Sight Medical Products Inc develops, manufactures and markets implantable prosthetic devices, to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, France and Germany, of which key revenue is derived from the United States.


Your Recent History
NASDAQ
EYES
Second Sig..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.